Amifampridina fosfato

( DrugBank: - / KEGG DRUG: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
3	Spinal muscular atrophy	2

ID	Disease name (Link within this page)	Number of trials
11	Myasthenia gravis	2

3. Spinal muscular atrophy

Clinical trials : 237 / Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-000160-28-IT (EUCTR)	06/11/2018	24/05/2021	Clinical study evaluating the long term safety of amifampridine phosphate in ambulatory patients wit ...	Long term safety study of amifampridine phosphate in ambulatory patients with Spinal Muscular Atroph ...	Spinal Muscular Atrophy (SMA) Type 3 MedDRA version: 20.1;Level: PT;Classification code 10041582;Ter ...	Trade Name: FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE Produc ...	CATALYST PHARMACEUTICALS INC.	NULL	Not Recruiting			Female: yes Male: yes	12	Phase 2	Italy
2	EUCTR2017-004600-22-IT (EUCTR)	04/04/2018	07/04/2021	Clinical study evaluating the effect of Amifampridine Phosphate in Ambulatory Patients with Spinal M ...	A Randomized, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Amifampridi ...	Spinal Muscular Atrophy (SMA) Type 3 MedDRA version: 20.1;Level: PT;Classification code 10041582;Ter ...	Trade Name: FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE Produc ...	CATALYST PHARMACEUTICALS INC.	NULL	Not Recruiting			Female: yes Male: yes	12	Phase 2	Italy

Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-004777-14-IT (EUCTR)	05/06/2018	21/01/2021	Clinical study evaluating the long term safety of amifampridine phosphate in patients with MuSK anti ...	Long term safety study of amifampridine phosphate in patients with MuSK antibody positive and AChR a ...	MuSK antibody and AChR antibody positive myasthenia gravis MedDRA version: 21.1;Level: PT;Classifica ...	Trade Name: FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE Produc ...	CATALYST PHARMACEUTICALS INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	70	Phase 3	United States;Canada;Italy
2	EUCTR2017-004018-25-IT (EUCTR)	22/02/2018	19/01/2021	Clinical study evaluating the effect of Amifampridine phosphate in patients with MuSK antibody posit ...	A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosp ...	MuSK antibody positive myasthenia gravis MedDRA version: 21.1;Level: PT;Classification code 10028417 ...	Trade Name: FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE Produc ...	CATALYST PHARMACEUTICALS INC.	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 3	United States;Canada;Italy